Effects of inhaled brevetoxins in allergic airways: Toxin-allergen interactions and pharmacologic intervention

William M. Abraham, Andrea J. Bourdelais, Ashfaq Ahmed, Irakli Serebriakov, Daniel G. Baden

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

During a Florida red tide, brevetoxins produced by the dinoflagellate Karenia brevis become aerosolized and cause airway symptoms in humans, especially in those with pre-existing airway disease (e.g., asthma). To understand these toxin-induced airway effects, we used sheep with airway hypersensitivity to Ascaris suum antigen as a surrogate for asthmatic patients and studied changes in pulmonary airflow resistance (RL) after inhalation challenge with lysed cultures of K. brevis (crude brevetoxins). Studies were done without and with clinically available drugs to determine which might prevent/reverse these effects. Crude brevetoxins (20 breaths at 100 pg/mL; n = 5) increased RL 128 ± 6% (mean ± SE) over baseline. This bronchoconstriction was significantly reduced (% inhibition) after pretreatment with the glucocorticosteroid budesonide (49%), the β2 adrenergic agent albuterol (71%), the anticholinergic agent atropine (58%), and the histamine H1-antagonist diphenhydramine (47%). The protection afforded by atropine and diphenhydramine suggests that both cholinergic (vagal) and H1-mediated pathways contribute to the bronchoconstriction. The response to cutaneous toxin injection was also histamine mediated. Thus, the airway and skin data support the hypothesis that toxin activates mast cells in vivo. Albuterol given immediately after toxin challenge rapidly reversed the bronchoconstriction. Toxin inhalation increased airway kinins, and the response to inhaled toxin was enhanced after allergen challenge. Both factors could contribute to the increased sensitivity of asthmatic patients to toxin exposure. We conclude that K. brevis aerosols are potent airway constrictors. Clinically available drugs may be used to prevent or provide therapeutic relief for affected individuals.

Original languageEnglish
Pages (from-to)632-637
Number of pages6
JournalEnvironmental Health Perspectives
Volume113
Issue number5
DOIs
StatePublished - May 1 2005
Externally publishedYes

Fingerprint

Allergens
toxin
Bronchoconstriction
Diphenhydramine
Albuterol
Atropine
Inhalation
Harmful Algal Bloom
Histamine H1 Antagonists
Ascaris suum
Dinoflagellida
Budesonide
Skin
Kinins
Preexisting Condition Coverage
drug
Cholinergic Antagonists
Aerosols
Mast Cells
Pharmaceutical Preparations

Keywords

  • Animal models
  • Asthma
  • Brevetoxin
  • Bronchoconstriction
  • Clinical therapies

ASJC Scopus subject areas

  • Environmental Science(all)
  • Environmental Chemistry
  • Public Health, Environmental and Occupational Health

Cite this

Effects of inhaled brevetoxins in allergic airways : Toxin-allergen interactions and pharmacologic intervention. / Abraham, William M.; Bourdelais, Andrea J.; Ahmed, Ashfaq; Serebriakov, Irakli; Baden, Daniel G.

In: Environmental Health Perspectives, Vol. 113, No. 5, 01.05.2005, p. 632-637.

Research output: Contribution to journalArticle

Abraham, William M. ; Bourdelais, Andrea J. ; Ahmed, Ashfaq ; Serebriakov, Irakli ; Baden, Daniel G. / Effects of inhaled brevetoxins in allergic airways : Toxin-allergen interactions and pharmacologic intervention. In: Environmental Health Perspectives. 2005 ; Vol. 113, No. 5. pp. 632-637.
@article{c13fb06e3afe489d9ac23b719264fede,
title = "Effects of inhaled brevetoxins in allergic airways: Toxin-allergen interactions and pharmacologic intervention",
abstract = "During a Florida red tide, brevetoxins produced by the dinoflagellate Karenia brevis become aerosolized and cause airway symptoms in humans, especially in those with pre-existing airway disease (e.g., asthma). To understand these toxin-induced airway effects, we used sheep with airway hypersensitivity to Ascaris suum antigen as a surrogate for asthmatic patients and studied changes in pulmonary airflow resistance (RL) after inhalation challenge with lysed cultures of K. brevis (crude brevetoxins). Studies were done without and with clinically available drugs to determine which might prevent/reverse these effects. Crude brevetoxins (20 breaths at 100 pg/mL; n = 5) increased RL 128 ± 6{\%} (mean ± SE) over baseline. This bronchoconstriction was significantly reduced ({\%} inhibition) after pretreatment with the glucocorticosteroid budesonide (49{\%}), the β2 adrenergic agent albuterol (71{\%}), the anticholinergic agent atropine (58{\%}), and the histamine H1-antagonist diphenhydramine (47{\%}). The protection afforded by atropine and diphenhydramine suggests that both cholinergic (vagal) and H1-mediated pathways contribute to the bronchoconstriction. The response to cutaneous toxin injection was also histamine mediated. Thus, the airway and skin data support the hypothesis that toxin activates mast cells in vivo. Albuterol given immediately after toxin challenge rapidly reversed the bronchoconstriction. Toxin inhalation increased airway kinins, and the response to inhaled toxin was enhanced after allergen challenge. Both factors could contribute to the increased sensitivity of asthmatic patients to toxin exposure. We conclude that K. brevis aerosols are potent airway constrictors. Clinically available drugs may be used to prevent or provide therapeutic relief for affected individuals.",
keywords = "Animal models, Asthma, Brevetoxin, Bronchoconstriction, Clinical therapies",
author = "Abraham, {William M.} and Bourdelais, {Andrea J.} and Ashfaq Ahmed and Irakli Serebriakov and Baden, {Daniel G.}",
year = "2005",
month = "5",
day = "1",
doi = "10.1289/ehp.7498",
language = "English",
volume = "113",
pages = "632--637",
journal = "Environmental Health Perspectives",
issn = "0091-6765",
publisher = "Public Health Services, US Dept of Health and Human Services",
number = "5",

}

TY - JOUR

T1 - Effects of inhaled brevetoxins in allergic airways

T2 - Toxin-allergen interactions and pharmacologic intervention

AU - Abraham, William M.

AU - Bourdelais, Andrea J.

AU - Ahmed, Ashfaq

AU - Serebriakov, Irakli

AU - Baden, Daniel G.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - During a Florida red tide, brevetoxins produced by the dinoflagellate Karenia brevis become aerosolized and cause airway symptoms in humans, especially in those with pre-existing airway disease (e.g., asthma). To understand these toxin-induced airway effects, we used sheep with airway hypersensitivity to Ascaris suum antigen as a surrogate for asthmatic patients and studied changes in pulmonary airflow resistance (RL) after inhalation challenge with lysed cultures of K. brevis (crude brevetoxins). Studies were done without and with clinically available drugs to determine which might prevent/reverse these effects. Crude brevetoxins (20 breaths at 100 pg/mL; n = 5) increased RL 128 ± 6% (mean ± SE) over baseline. This bronchoconstriction was significantly reduced (% inhibition) after pretreatment with the glucocorticosteroid budesonide (49%), the β2 adrenergic agent albuterol (71%), the anticholinergic agent atropine (58%), and the histamine H1-antagonist diphenhydramine (47%). The protection afforded by atropine and diphenhydramine suggests that both cholinergic (vagal) and H1-mediated pathways contribute to the bronchoconstriction. The response to cutaneous toxin injection was also histamine mediated. Thus, the airway and skin data support the hypothesis that toxin activates mast cells in vivo. Albuterol given immediately after toxin challenge rapidly reversed the bronchoconstriction. Toxin inhalation increased airway kinins, and the response to inhaled toxin was enhanced after allergen challenge. Both factors could contribute to the increased sensitivity of asthmatic patients to toxin exposure. We conclude that K. brevis aerosols are potent airway constrictors. Clinically available drugs may be used to prevent or provide therapeutic relief for affected individuals.

AB - During a Florida red tide, brevetoxins produced by the dinoflagellate Karenia brevis become aerosolized and cause airway symptoms in humans, especially in those with pre-existing airway disease (e.g., asthma). To understand these toxin-induced airway effects, we used sheep with airway hypersensitivity to Ascaris suum antigen as a surrogate for asthmatic patients and studied changes in pulmonary airflow resistance (RL) after inhalation challenge with lysed cultures of K. brevis (crude brevetoxins). Studies were done without and with clinically available drugs to determine which might prevent/reverse these effects. Crude brevetoxins (20 breaths at 100 pg/mL; n = 5) increased RL 128 ± 6% (mean ± SE) over baseline. This bronchoconstriction was significantly reduced (% inhibition) after pretreatment with the glucocorticosteroid budesonide (49%), the β2 adrenergic agent albuterol (71%), the anticholinergic agent atropine (58%), and the histamine H1-antagonist diphenhydramine (47%). The protection afforded by atropine and diphenhydramine suggests that both cholinergic (vagal) and H1-mediated pathways contribute to the bronchoconstriction. The response to cutaneous toxin injection was also histamine mediated. Thus, the airway and skin data support the hypothesis that toxin activates mast cells in vivo. Albuterol given immediately after toxin challenge rapidly reversed the bronchoconstriction. Toxin inhalation increased airway kinins, and the response to inhaled toxin was enhanced after allergen challenge. Both factors could contribute to the increased sensitivity of asthmatic patients to toxin exposure. We conclude that K. brevis aerosols are potent airway constrictors. Clinically available drugs may be used to prevent or provide therapeutic relief for affected individuals.

KW - Animal models

KW - Asthma

KW - Brevetoxin

KW - Bronchoconstriction

KW - Clinical therapies

UR - http://www.scopus.com/inward/record.url?scp=19044381103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19044381103&partnerID=8YFLogxK

U2 - 10.1289/ehp.7498

DO - 10.1289/ehp.7498

M3 - Article

C2 - 15866776

AN - SCOPUS:19044381103

VL - 113

SP - 632

EP - 637

JO - Environmental Health Perspectives

JF - Environmental Health Perspectives

SN - 0091-6765

IS - 5

ER -